Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

New Wave Of Clinical Trials May Throw Indian Regulators Off Balance - DIA Conference

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - India's ability to handle a growing number of clinical trial applications has reached a tipping point as ethics committees, regulators and other stakeholders struggle to meet demand which is expected to double in 2008, industry officials said

You may also be interested in...



PharmAsia News Notable Notes: Kotak Initiates Coverage Of Five Indian CMO, CRO Firms

NEW DELHI - Efforts by five smaller Indian drug companies to attract contract research and manufacturing stand to benefit from multinational firms cost-cutting efforts in sourcing active pharmaceutical ingredients and increased clinical trials in the country

PharmAsia News Notable Notes: Kotak Initiates Coverage Of Five Indian CMO, CRO Firms

NEW DELHI - Efforts by five smaller Indian drug companies to attract contract research and manufacturing stand to benefit from multinational firms cost-cutting efforts in sourcing active pharmaceutical ingredients and increased clinical trials in the country

Negative Perceptions of Clinical Trials In India Persist – Clinical Trials Panel

SAN FRANCISCO - Companies looking to initiate clinical trials in India must tread lightly when navigating ethics committees, according to panelists at a recent conference on various aspects of entering clinical trials in Asia

Latest Headlines
See All
UsernamePublicRestriction

Register

SC068358

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel